Neurocrine Biosciences Quarterly Balance Sheet
NASDAQ: NBIXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Neurocrine Biosciences financial position
As of Jun 30, 2026, Neurocrine Biosciences reported total assets of $5.36 billion, up 37.8% from a year earlier against total liabilities of $1.67 billion. Shareholders' equity stood at $3.69 billion, or 68.9% of assets. The company held $332.4 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 1.87, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Neurocrine Biosciences balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 332.40M | 266.50M | 713.00M | 340.20M | 264.00M | 194.10M | 233.00M | 349.10M | 139.70M | 396.30M | 251.10M | 293.70M |
| Short-Term Investments | 57.40M | 1.05B | 767.40M | 774.60M | 711.60M | 749.40M | 843.10M | 878.90M | 899.20M | 814.30M | 780.50M | 801.40M |
| Receivables | 887.00M | 768.10M | 686.80M | 728.00M | 595.70M | 516.00M | 479.10M | 481.10M | 468.20M | 450.70M | 439.30M | 417.80M |
| Inventory | 104.20M | 64.50M | 69.00M | 69.30M | 56.90M | 59.10M | 57.40M | 45.80M | 42.50M | 37.20M | 38.30M | 28.80M |
| Total Current Assets | 1.64B | 2.44B | 2.52B | 2.16B | 1.75B | 1.64B | 1.72B | 1.88B | 1.67B | 1.80B | 1.61B | 1.65B |
| Property, Plant & Equipment | 90.50M | 90.90M | 89.80M | 97.30M | 91.70M | 87.00M | 82.60M | 80.00M | 80.10M | 75.30M | 70.80M | 68.80M |
| Goodwill | 500.60M | 6.00M | 6.10M | — | — | — | 5.70M | 6.10M | 5.70M | 5.70M | 5.80M | 5.50M |
| Intangible Assets | 2.23B | — | 4.70M | 35.70M | 37.20M | 36.40M | 36.50M | 34.50M | 33.50M | 34.30M | 35.50M | 34.90M |
| Long-Term Investments | 91.90M | 1.33B | 1.06B | 998.50M | 873.80M | 815.30M | 739.50M | 643.90M | 637.80M | 700.40M | 687.50M | 454.70M |
| Total Assets | 5.36B | 4.91B | 4.63B | 4.27B | 3.89B | 3.69B | 3.72B | 3.54B | 3.31B | 3.47B | 3.25B | 2.85B |
| Accounts Payable | 808.30M | 773.00M | 674.30M | 584.30M | 489.50M | 475.20M | 461.60M | 392.70M | 358.50M | 417.20M | 448.80M | 503.00M |
| Total Current Liabilities | 874.50M | 831.70M | 743.40M | 638.00M | 546.30M | 522.90M | 507.70M | 429.70M | 398.50M | 712.90M | 654.80M | 691.60M |
| Total Liabilities | 1.67B | 1.50B | 1.38B | 1.26B | 1.20B | 1.15B | 1.13B | 816.10M | 795.80M | 1.09B | 1.02B | 846.10M |
| Shareholders' Equity | 3.69B | 3.41B | 3.25B | 3.00B | 2.69B | 2.54B | 2.59B | 2.72B | 2.51B | 2.39B | 2.23B | 2.00B |
| Retained Earnings | 724.00M | 589.60M | 447.70M | 294.00M | 84.50M | -5.30M | 29.20M | 81.10M | -48.70M | -113.70M | -157.10M | -304.80M |
| Net Cash (Debt) | 389.80M | 1.32B | 1.48B | 1.11B | 975.60M | 943.50M | 1.08B | 1.23B | 1.04B | 1.21B | 1.03B | 1.10B |
| Shares Outstanding | 101.60M | 100.60M | 100.10M | 99.70M | 99.00M | 99.00M | 99.40M | 101.20M | 100.90M | 100.60M | 98.70M | 98.20M |
This table shows 12 quarterly periods of Neurocrine Biosciences's balance sheet, from Q2 2026 back to Q3 2023, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow NBIX's reporting calendar. What is a balance sheet?